Precision Medicine Intelligence - evidence scoring evaluating the clinical actionability of BRAF V600E in multiple non-melanoma solid tumors

Drugs Today (Barc). 2016 Jul;52(7):399-405. doi: 10.1358/dot.2016.52.7.2533855.

Abstract

With the ever-increasing growth of next-generation sequencing literature, how can researchers and clinicians assess clinical actionability and utility and objectively assign confidence to gene variant-phenotype associations? This article presents an informatics solution for clinical interpretation of patient-derived genomic and molecular data containing manually curated scientific evidence supporting gene variant-disease and -drug response phenotypes in somatic cancers. An algorithm for direct evidence scoring will be used to demonstrate the diverse utility of BRAF V600E in treating many common cancers.

Keywords: BRAF V600E; Precision medicine.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Animals
  • Computational Biology
  • Evidence-Based Medicine / methods*
  • Genetic Variation
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Neoplasms / genetics
  • Precision Medicine / methods*
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism*

Substances

  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf